Ina Research, Japan SLC, and DNA Link join forces for the effective use of PDX mouse models

2018/11/09

Ina Research, Japan SLC, and DNA Link join forces for the effective use of PDX mouse models
First-ever production and commercial use in Japan

July 2018, Ina Research, Japan SLC, and Korea’s DNA Link launched a joint project for the effective use of “PDX (Patient derived xenograft) mouse models,” in which patient-derived cancer cells are transplanted into the living body of a mouse for the development of pharmaceutical products.

Japan SLC, a provider of laboratory animals, will produce PDX models using cancer cells of Asian patients provided by DNA Link, which owns the library of human cancer cells.
Ina Research will then use the optimal PDX model to conduct drug efficacy tests of anticancer drugs in non-clinical studies entrusted by pharmaceutical companies and academia.

PDX models, which are often used in drug efficacy tests of anticancer drugs, are considered to be promising models that improve the ability to predict therapeutic effects because they use human cancer cells and are thus close to the human body environment. The models are optimal particularly in their antitumor and tumor growth suppression effects, and are used for research that requires living tumor cells, such as studies that investigate the functional significance of a new found gene abnormality and the mechanism of a novel compound.

DNK Link has a library that stocks about seven types for carcinomas and 200 types for lung cancer and brain tumors. Its collects samples from various kinds of hospitals and can evaluate them according to a patient’s background, such as a cancer in which a specific genotype is expressed. 
DNA Link has been characterizing all samples with next generation sequencing, and providing gene information as well.

Please go to the website and check DNA Link’s library.
http://www.dnalink.com/english/